Enanta Pharmaceuticals, Inc. (ENTA)

Over the past six months, Enanta's stock price has fluctuated, reaching $13.43 on April 7, 2026, a 201.12% increase from April 8, 2025. Key events include a public offering in October 2025, positive data from the RSVHR study in November 2025, R&D updates in January 2026, quarterly earnings in February 2026, and presentations at scientific conferences in March and April 2026.

Demand seasonality for Enanta Pharmaceuticals' products is primarily influenced by the seasonal patterns of Respiratory Syncytial Virus (RSV) infections. Clinical trials for RSV candidates are planned around these seasonal patterns. Royalty revenue from HCV products provides a more consistent revenue stream independent of seasonal viral outbreaks.

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule drugs for viral infections and immunological diseases. Their pipeline includes Zelicapavir (EDP-938) for RSV, EDP-323 for RSV, EDP-514 for HBV, EDP-235 for human coronaviruses, EDP-978 (KIT inhibitor) for CSU, EPS-3903 for atopic dermatitis, and Glecaprevir and Paritaprevir for HCV through a collaboration with AbbVie.

Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts, United States. While its research and development are based in the U.S., its HCV treatments, developed in collaboration with AbbVie, are sold globally.

Enanta Pharmaceuticals' brand reputation is tied to its clinical development progress and intellectual property. Positive clinical data from the Phase 2b RSVHR study for zelicapavir and advancements in its RSV and immunology pipelines have positively impacted its reputation. Patent litigation, such as the lawsuit against Pfizer regarding Paxlovid, also affects its reputation.

Institutional investors hold a significant portion of Enanta Pharmaceuticals, Inc.'s shares, accounting for 85.68% of the shares. Major institutional owners include Janus Henderson Group Plc, BlackRock, Inc., and Farallon Capital Management Llc. Individuals hold 5.09% of the shares.